Skip to main content

Table 1 Selected genes derived from ICA & GO analysis of gene array experiments. Genes are combined into ontologies. Average Fold Changes are calculated from normalised values over the number of spots shown for each gene. As can be seen, not all genes are differentially expressed according to t-test p-values. Genes are instead selected based on their ICA loading (see discussion)

From: In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer

GO Description

Gene symbol

Description

No of spots

Ave FC

Ave ttest p

activation of MAPKKK (GO:0000185)

GADD45B

growth arrest and DNA-damage-inducible, beta

2

2.6

0.090

cell cycle arrest (GO:0007050)

EIF4G2

eukaryotic translation initiation factor 4 gamma, 2

2

1.2

0.249

 

GADD45A

growth arrest and DNA-damage-inducible, alpha

2

5.1

0.003

 

PPP1R15A

protein phosphatase 1, regulatory (inhibitor) subunit 15A

2

1.4

0.085

 

PR48

protein phosphatase 2A 48 kDa regulatory subunit

1

-1.1

0.427

 

SESN3

sestrin 3

2

-1.3

0.161

 

TP53

tumor protein p53 (Li-Fraumeni syndrome)

4

1.7

0.036

cell death (GO:0008219)

EIF4G2

eukaryotic translation initiation factor 4 gamma, 2

2

1.2

0.249

 

EMP3

epithelial membrane protein 3

2

1.7

0.111

cell growth (GO:0016049)

P8

p8 protein (candidate of metastasis 1)

2

3.1

0.005

 

SLC3A2

solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2

4

2.0

0.012

cell proliferation (GO:0008283)

EGFR

epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)

2

2.2

0.009

 

FTH1

ferritin, heavy polypeptide 1

1

1.2

0.301

 

IGFBP4

insulin-like growth factor binding protein 4

2

1.8

0.002

 

OSMR

oncostatin M receptor

2

1.7

0.088

 

PDGFA

platelet-derived growth factor alpha polypeptide

2

1.5

0.032

 

PDGFB

platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)

4

2.2

0.083

 

SYK

spleen tyrosine kinase

2

-1.1

0.631

 

TGFA

transforming growth factor, alpha

2

-1.0

0.907

 

TGFBI

transforming growth factor, beta-induced, 68kDa

2

2.1

0.164

 

TP53

tumor protein p53 (Li-Fraumeni syndrome)

4

1.7

0.036

 

VEGF

vascular endothelial growth factor

2

6.6

0.175

G1/S transition of mitotic cell cycle (GO:0000082)

CCND1

cyclin D1 (PRAD1: parathyroid adenomatosis 1)

2

-1.3

0.168

insulin-like growth factor binding (GO:0005520)

CYR61

cysteine-rich, angiogenic inducer, 61

2

2.9

0.013

 

KAZALD1

Kazal-type serine protease inhibitor domain 1

2

-1.1

0.770

 

IGFBP4

insulin-like growth factor binding protein 4

2

1.8

0.002

 

CTGF

connective tissue growth factor

2

2.9

0.006

 

IGFBP5

insulin-like growth factor binding protein 5

4

2.7

0.041

metalloprotease inhibitor (GO:0008191)

TIMP1

tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)

3

1.4

0.250

methionine adenosyltransferase (GO:0004478)

MAT2A

methionine adenosyltransferase II, alpha

4

-2.9

0.001

methionine-tRNA ligase (GO:0004825)

MARS

methionine-tRNA synthetase

2

6.7

0.006

Back to article page

Molecular Cancer

ISSN: 1476-4598